AzitraAZTR
About: Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Employees: 10
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
8% more capital invested
Capital invested by funds: $58.5K [Q2] → $62.9K (+$4.47K) [Q3]
0.55% less ownership
Funds ownership: 2.07% [Q2] → 1.52% (-0.55%) [Q3]
25% less funds holding
Funds holding: 8 [Q2] → 6 (-2) [Q3]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for AZTR.
